IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice

Vincenzo Bronte(University of Padua), Paolo Serafini(University of Padua), Carmela De Santo(University of Padua), Ilaria Marigo(University of Padua), Valeria Tosello(University of Padua), Alessandra Mazzoni(National Institutes of Health), David M. Segal(National Institutes of Health), Caroline Staib(Institut de Virologie), Marianne Löwel(Institut de Virologie), Gerd Sutter(Institut de Virologie), Mario P. Colombo(Tumori Foundation), Paola Zanovello(University of Padua)
The Journal of Immunology
January 1, 2003
Cited by 505Open Access
Full Text

Abstract

We previously demonstrated that a specialized subset of immature myeloid cells migrate to lymphoid organs as a result of tumor growth or immune stress, where they suppress B and T cell responses to Ags. Although NO was required for suppression of mitogen activation of T cells by myeloid suppressor cells (MSC), it was not required for suppression of allogenic responses. In this study, we describe a novel mechanism used by MSC to block T cell proliferation and CTL generation in response to alloantigen, which is mediated by the enzyme arginase 1 (Arg1). We show that Arg1 increases superoxide production in myeloid cells through a pathway that likely utilizes the reductase domain of inducible NO synthase (iNOS), and that superoxide is required for Arg1-dependent suppression of T cell function. Arg1 is induced by IL-4 in freshly isolated MSC or cloned MSC lines, and is therefore up-regulated by activated Th2, but not Th1, cells. In contrast, iNOS is induced by IFN-gamma and Th1 cells. Because Arg1 and iNOS share L-arginine as a common substrate, our results indicate that L-arginine metabolism in myeloid cells is a potential target for selective intervention in reversing myeloid-induced dysfunction in tumor-bearing hosts.


Related Papers

No related papers found

Powered by citation graph analysis